CompletedNot Applicable

HUMIRA® Long-term Treatment in Patients With Non-infectious Intermediate-, Posterior-, or Pan-uveitis

Japan259 participantsStarted 2016-11-15

Plain-language summary

This study evaluates the long- term safety and effectiveness of adalimumab in participants with non-infectious intermediate-, posterior-, or pan-uveitis in daily practice in Japan.

Who can participate

Age range0 Years – 100 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Participants receiving adalimumab for the treatment of Non-infectious Intermediate-, Posterior-, or Pan-uveitis Exclusion Criteria: * Participants previously treated with adalimumab

What they're measuring

Incidence of adverse drug reactions (ADR)

Timeframe: Up to Week 52

Trial details

NCT IDNCT02916017

SponsorAbbVie

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2020-10-14

View on ClinicalTrials.gov More Uveitis trials